Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

US Food and Drug Administration

Lack of robust post-approval studies under FDA system

Review of drugs approved on the basis of limited evidence concludes that stricter rules are needed for post-approval studies.

The US Food and Drug Administration (FDA) has increasingly adopted the approach of approving novel drugs on the basis of limited evidence, enabling them to come to the market quicker, on the understanding that post-approval assessments will be carried out.

Researchers systematically reviewed the evidence on all 117 drugs approved for 123 indications between 2005 and 2012 by the FDA on the basis of a single pivotal trial and/or using surrogate disease markers as primary endpoints.

They found that, after a median of 5.5 years post-approval, fewer than one-third of those approved based on a single trial had a published randomised clinical trial showing superior efficacy versus a comparator. And less than 1 in 10 approved using surrogate endpoints had a subsequent trial demonstrating efficacy on the basis of clinical outcomes.

Reporting in The BMJ[1] (online, 3 May 2017), the researchers say that stricter rules for post-approval studies should be enforced to make sure high-quality evidence is available to inform clinical practice.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203062

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Main entrance of the US Food and Drug Administration (FDA)

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.